EVEREST-Outcomes

Posted by on

The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure - The Journal of the American Medical Association - 2007

Brief Summary:

In patients with HFrEF on standard therapy, tolvaptan has no effect on either all-cause mortality or a composite of CV mortality or HF rehospitalization when given for 60 days following an acute HF episode.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/17384437

Comments

Post a Comment

Drop your thoughts here, we would love to hear from you